These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 19098118

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Acute in vivo resistance in high-dose therapy.
    Teicher BA, Ara G, Keyes SR, Herbst RS, Frei E.
    Clin Cancer Res; 1998 Feb; 4(2):483-91. PubMed ID: 9516940
    [Abstract] [Full Text] [Related]

  • 4. Benzethonium chloride: a novel anticancer agent identified by using a cell-based small-molecule screen.
    Yip KW, Mao X, Au PY, Hedley DW, Chow S, Dalili S, Mocanu JD, Bastianutto C, Schimmer A, Liu FF.
    Clin Cancer Res; 2006 Sep 15; 12(18):5557-69. PubMed ID: 17000693
    [Abstract] [Full Text] [Related]

  • 5. Erufosine, an alkylphosphocholine, with differential toxicity to human cancer cells and bone marrow cells.
    Bagley RG, Kurtzberg L, Rouleau C, Yao M, Teicher BA.
    Cancer Chemother Pharmacol; 2011 Dec 15; 68(6):1537-46. PubMed ID: 21526352
    [Abstract] [Full Text] [Related]

  • 6. Influence of schedule on alkylating agent cytotoxicity in vitro and in vivo.
    Teicher BA, Holden SA, Eder JP, Brann TW, Jones SM, Frei E.
    Cancer Res; 1989 Nov 01; 49(21):5994-8. PubMed ID: 2790813
    [Abstract] [Full Text] [Related]

  • 7. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
    Lobell RB, Omer CA, Abrams MT, Bhimnathwala HG, Brucker MJ, Buser CA, Davide JP, deSolms SJ, Dinsmore CJ, Ellis-Hutchings MS, Kral AM, Liu D, Lumma WC, Machotka SV, Rands E, Williams TM, Graham SL, Hartman GD, Oliff AI, Heimbrook DC, Kohl NE.
    Cancer Res; 2001 Dec 15; 61(24):8758-68. PubMed ID: 11751396
    [Abstract] [Full Text] [Related]

  • 8. In vitro assays of chemotherapeutic sensitivity.
    Carney DN, Winkler CF.
    Important Adv Oncol; 1985 Dec 15; ():78-103. PubMed ID: 3916747
    [Abstract] [Full Text] [Related]

  • 9. Evaluating response to antineoplastic drug combinations in tissue culture models.
    Reynolds CP, Maurer BJ.
    Methods Mol Med; 2005 Dec 15; 110():173-83. PubMed ID: 15901935
    [Abstract] [Full Text] [Related]

  • 10. Response of the FSaII fibrosarcoma to antiangiogenic modulators plus cytotoxic agents.
    Teicher BA, Holden SA, Ara G, Northey D.
    Anticancer Res; 1993 Dec 15; 13(6A):2101-6. PubMed ID: 7507654
    [Abstract] [Full Text] [Related]

  • 11. Effects of RSR13 and oxygen on the cytotoxicity of cisplatin and carboplatin to EMT6 mouse mammary tumor cells in vitro and in vivo.
    Donnelly ET, Kelley M, Rockwell S.
    Cancer Chemother Pharmacol; 2004 Jan 15; 53(1):43-50. PubMed ID: 14574460
    [Abstract] [Full Text] [Related]

  • 12. Bone marrow CFU-GM and human tumor xenograft efficacy of three tubulin binding agents.
    Kurtzberg LS, Roth SD, Bagley RG, Rouleau C, Yao M, Crawford JL, Krumbholz RD, Schmid SM, Teicher BA.
    Cancer Chemother Pharmacol; 2009 Oct 15; 64(5):1029-38. PubMed ID: 19277662
    [Abstract] [Full Text] [Related]

  • 13. Effects of SU101 in combination with cytotoxic agents on the growth of subcutaneous tumor xenografts.
    Strawn LM, Kabbinavar F, Schwartz DP, Mann E, Shawver LK, Slamon DJ, Cherrington JM.
    Clin Cancer Res; 2000 Jul 15; 6(7):2931-40. PubMed ID: 10914743
    [Abstract] [Full Text] [Related]

  • 14. Modulation of alkylating agents by etanidazole and Fluosol-DA/carbogen in the FSaIIC fibrosarcoma and EMT6 mammary carcinoma.
    Teicher BA, Herman TS, Tanaka J, Eder JP, Holden SA, Bubley G, Coleman CN, Frei E.
    Cancer Res; 1991 Feb 15; 51(4):1086-91. PubMed ID: 1825474
    [Abstract] [Full Text] [Related]

  • 15. Clinical studies on a new screening assay for anticancer agents using nude mice and isotopic evaluation.
    Noso Y, Niimi K, Nishiyama M, Hirabayashi N, Toge T, Niimoto M, Hattori T.
    Cancer Res; 1987 Dec 01; 47(23):6418-22. PubMed ID: 3677085
    [Abstract] [Full Text] [Related]

  • 16. Paclitaxel/carboplatin administration along with antiangiogenic therapy in non-small-cell lung and breast carcinoma models.
    Herbst RS, Takeuchi H, Teicher BA.
    Cancer Chemother Pharmacol; 1998 Dec 01; 41(6):497-504. PubMed ID: 9554595
    [Abstract] [Full Text] [Related]

  • 17. Combination of N,N',N"-triethylenethiophosphoramide and cyclophosphamide in vitro and in vivo.
    Teicher BA, Holden SA, Cucchi CA, Cathcart KN, Korbut TT, Flatow JL, Frei E.
    Cancer Res; 1988 Jan 01; 48(1):94-100. PubMed ID: 3121169
    [Abstract] [Full Text] [Related]

  • 18. Transforming growth factor-beta 1 overexpression produces drug resistance in vivo: reversal by decorin.
    Teicher BA, Ikebe M, Ara G, Keyes SR, Herbst RS.
    In Vivo; 1997 Jan 01; 11(6):463-72. PubMed ID: 9509296
    [Abstract] [Full Text] [Related]

  • 19. Effects of cepharanthine alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice.
    Harada K, Ferdous T, Itashiki Y, Takii M, Mano T, Mori Y, Ueyama Y.
    Anticancer Res; 2009 Apr 01; 29(4):1263-70. PubMed ID: 19414373
    [Abstract] [Full Text] [Related]

  • 20. [Ex-vivo-chemoresponse testing of head and neck cancer: an old hat?].
    Wichmann G, Körner C, Dietz A.
    Laryngorhinootologie; 2011 Aug 01; 90(8):464-8. PubMed ID: 21809229
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.